SCHEMBL6005012

SCHEMBL6005012

CN([C]=O)n1ccc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 9/20 0.50
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
NOTUM Q6P988 1/20 0.42
CDK4 P11802 3/20 0.38
CCND1 P24385 3/20 0.38
CA12 O43570 1/20 0.36
BRD4 O60885 1/20 0.36
BRPF1 P55201 1/20 0.36
CA9 Q16790 1/20 0.36
KAT2B Q92831 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 2/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PRKD3 O94806 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
PRKCA P17252 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006493 0.81 SLC6A2 (0.50) SLC6A2HTR2AHTR2CNOTUMCDK4
SCHEMBL3365470 0.78 SLC6A2 (0.58) SLC6A2HTR2AHTR2CNOTUMCDK4
SCHEMBL10975857 0.73 NOTUM (0.53) SLC6A2HTR2AHTR2CNOTUMCDK4
SCHEMBL4102885 0.73 SLC6A2 (0.49) SLC6A2HTR2AHTR2CNOTUMKMT2A
SCHEMBL6625810 0.72 SLC6A2 (0.75) SLC6A2HTR2AHTR2CNOTUMCDK4
SCHEMBL8118593 0.69 SLC6A2 (0.49) SLC6A2HTR2AHTR2CNOTUMCDK4
SCHEMBL6006426 0.69 SLC6A2 (0.46) SLC6A2KMT2ATSHRRAB9AL3MBTL1
SCHEMBL6008133 0.68 GPR3 (0.44) SLC6A2KMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL8836092 0.68 SLC6A2 (0.44) SLC6A2HTR2AHTR2CNOTUMCDK4
SCHEMBL8836095 0.68 LMNA (0.49) SLC6A2HTR2AHTR2CNOTUMCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 SLC6A2 1120/4885HTR2A 305/4885HTR2C 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.